stockrow
Saturday 7 November 2026
Export SRZN’s income statement to Excel — free account
Surrozen, Inc.
SRZN Healthcare Biotechnology
Surrozen, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.5 million, down 67.4% from fiscal 2024.
- Revenue
- +408.7%
- EPS
- +7.84%
- Free cash flow
- −21.3%
Quarter to June 2026, against a year earlier
31.15
2.15
+7.41%
Follow SRZN
Alert me
Surrozen, Inc. (SRZN) P/E ratio
Surrozen, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2022 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 5 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| IRD Opus Genetics, Inc. compare | n/m |
| OBIO Orchestra BioMed Holdings, Inc. compare | n/m |
| AVIR Atea Pharmaceuticals, Inc. compare | n/m |
| CTNM Contineum Therapeutics, Inc. compare | n/m |
| RZLT Rezolute, Inc. compare | n/m |
| MPLT MapLight Therapeutics, Inc. compare | n/m |
| AUTL Autolus Therapeutics PLC Sponsored ADR compare | n/m |
| SRZN Surrozen, Inc. | n/m |
| AGMB AgomAb Therapeutics NV compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)